



DEWIPAT No. 30.031.10.US  
UNITED STATES PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT

Application Number	10/608,305
Filing Date	June 27, 2003
First Named Inventor	Liang C. Dong et al.
Title	Controlled Release Capsule for Delivery of Liquid Formulation
Art Unit	1614
Confirmation Number	8986
Examiner Name	
Attorney Docket Number	ARC 3251R1

Applicant submits:

References listed on the attached form PTO 1449\*.

- Copies of the references are enclosed (U.S. patents/applications omitted if filing date is after June 30, 2003).
- A copy of a communication from a foreign patent office in a counterpart application is enclosed.
- English language version of foreign search report indicating degree of relevance is enclosed.

Under 35 USC 120, this application relies on the earlier filing date of application serial number \_\_\_\_\_, filed on \_\_\_\_\_. The following references were submitted to and/or cited by the Office in the prior application and, therefore, are not provided in this application.

---



---



---



---



---



---

This statement is being filed:

- with the application.
- within three months of the filing date of the application.
- before the receipt of a first Office Action on the merits.
- after a first Office Action on the merits, but before receipt of a final Office Action or a Notice of Allowance.
  - I, the undersigned, hereby certify that each item of information contained in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated \_\_\_\_\_, which is not more than three months prior to filing of this statement.
- after a first Office Action on the merits, but before receipt of a final Office Action or a Notice of Allowance.
  - Late submission fee \$ \_\_\_\_\_ under 37 CFR 1.17(p) is enclosed.
- after a final Office Action or a Notice of Allowance, but before payment of the issue fee. I, the undersigned, hereby certify that each item of information in this statement was cited in a communication from a foreign patent office in a counterpart foreign application, the communication being dated \_\_\_\_\_, which is not more than three months prior to filing this statement. Applicant hereby petitions under CFR 1.97(d) for this statement to be considered.
  - Submission fee \$ \_\_\_\_\_ under 37 CFR 1.17(p) is enclosed.
- Please apply any additional charges or credits to Deposit Account No. \_\_\_\_\_.

SIGNATURE OF Applicant, Attorney, or Agent

Name	Adenike A. Adewuya	Registration No.	42,254
Signature	<i>Adenike Adewuya</i>		
Date	2/24/2004	Telephone	281-477-3450

\*Total of 1 form PTO-1449 are submitted.



DEWIPAT No. 30.031.10.US

UNITED STATES PATENT AND TRADEMARK OFFICE

**INFORMATION DISCLOSURE  
CITATION  
(MODIFIED FORM PTO-1449)**

				Application Number	10/608,305
				Filing Date	June 27, 2003
				First Named Inventor	Liang C. Dong et al.
				Title	Controlled Release Capsule for Delivery of Liquid Formulation
				Art Unit	1614
				Confirmation Number	8986
				Examiner Name	
Sheet	1	of	1	Attorney Docket Number	ARC 3251R1

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number	Publication Date	Applicant/Patentee
	A1	US-2001/0036472 A1	11/01/2001	Wong et al.
	A2	US-5,830,502	11/03/1998	Dong et al.
	A3	US-5,034,229	07/23/1991	Magruder et al.
	A4	US-4,111,202	09/05/1978	Theeuwes
		US-		

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number	Publication Date	Applicant/Patentee	T
	A5	WO 01/41742	06/14/2001	Alza Corporation	
	A6	WO 98/20930	05/22/1998	Alza Corporation	
	A7	WO 00/13674	03/16/2000	Alza Corporation	
	A8	WO 00/38655	07/06/2000	Alza Corporation	

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	A9	PCT International Search Report dated 11/05/2003 from Intl App No. PCT/US03/20422	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

The collection of this information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. **SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.**